DE602004023102D1 - Verfahren zur herstellung kristalliner formen von orlistat - Google Patents

Verfahren zur herstellung kristalliner formen von orlistat

Info

Publication number
DE602004023102D1
DE602004023102D1 DE602004023102T DE602004023102T DE602004023102D1 DE 602004023102 D1 DE602004023102 D1 DE 602004023102D1 DE 602004023102 T DE602004023102 T DE 602004023102T DE 602004023102 T DE602004023102 T DE 602004023102T DE 602004023102 D1 DE602004023102 D1 DE 602004023102D1
Authority
DE
Germany
Prior art keywords
orlistat
crystalline forms
preparing crystalline
relates
processes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004023102T
Other languages
English (en)
Inventor
Yatendra Kumar
Mohan Prasad
Keshav Deo
Anand Pandey
Killol Patel
Seema Kanwar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of DE602004023102D1 publication Critical patent/DE602004023102D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
    • C07D305/12—Beta-lactones
DE602004023102T 2003-09-12 2004-09-13 Verfahren zur herstellung kristalliner formen von orlistat Active DE602004023102D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1144DE2003 2003-09-12
PCT/IB2004/002957 WO2005026140A1 (en) 2003-09-12 2004-09-13 Process for the preparation of crystalline forms of orlistat

Publications (1)

Publication Number Publication Date
DE602004023102D1 true DE602004023102D1 (de) 2009-10-22

Family

ID=34308043

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004023102T Active DE602004023102D1 (de) 2003-09-12 2004-09-13 Verfahren zur herstellung kristalliner formen von orlistat

Country Status (6)

Country Link
EP (1) EP1673359B1 (de)
AT (1) ATE442361T1 (de)
DE (1) DE602004023102D1 (de)
ES (1) ES2329474T3 (de)
PT (1) PT1673359E (de)
WO (1) WO2005026140A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1763021B (zh) * 2005-09-29 2010-08-11 杭州华东医药集团生物工程研究所有限公司 一种提纯奥利司他的方法
EP1803714A1 (de) * 2005-12-27 2007-07-04 KRKA, tovarna zdravil, d.d., Novo mesto Verfahren zur Herstellung kristalliner Formen von Orlistat
EP1944025A1 (de) * 2007-01-09 2008-07-16 Ranbaxy Laboratories Limited Stabile pharmazeutische Zusammensetzungen mit Orlistat
EP2002825B1 (de) * 2007-06-14 2013-05-22 Krka Pharmazeutische Zubereitungen mit Orlistat
EP2141236A1 (de) 2008-07-03 2010-01-06 KRKA, D.D., Novo Mesto Verfahren zur Herstellung von Lipstatin und Mikroorganismen dafür
US8309107B2 (en) 2008-10-06 2012-11-13 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
WO2010084502A1 (en) * 2009-01-22 2010-07-29 Biocon Limited A crystalline form of orlistat and a process thereof
WO2010112222A1 (en) 2009-03-31 2010-10-07 Krka, D.D., Novo Mesto Progressive emulsion crystallization
CN102993135B (zh) * 2012-12-31 2015-09-09 山东新时代药业有限公司 一种奥利司他的纯化方法
CN107266395A (zh) * 2017-08-08 2017-10-20 中山万远新药研发有限公司 一种奥利司他ⅰ晶型的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60000796T2 (de) * 1999-01-29 2003-09-18 Hoffmann La Roche Reinigung von Lipstatin
US6730319B2 (en) * 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
WO2003047531A2 (en) * 2001-12-04 2003-06-12 Biogal Gyogyszergyar Rt Preparation of orlistat and orlistat crystalline forms

Also Published As

Publication number Publication date
ES2329474T3 (es) 2009-11-26
ATE442361T1 (de) 2009-09-15
EP1673359A1 (de) 2006-06-28
PT1673359E (pt) 2009-10-06
WO2005026140A1 (en) 2005-03-24
EP1673359B1 (de) 2009-09-09

Similar Documents

Publication Publication Date Title
ATE481096T1 (de) Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
MXPA05012061A (es) Preparacion y uso de derivados alquilarilo para el tratamiento de la obesidad.
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
ATE411280T1 (de) Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege
ATE492542T1 (de) Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas
EA200601553A1 (ru) Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
EP1673078A4 (de) Benzylether- und benzylamino-beta-sekretase-hemmer zur behandlung von alzheimer-krankheit
GB0305152D0 (en) Organic compounds
ATE432278T1 (de) Verbindungen zur behandlung von krankheiten
DE602007008616D1 (de) Verfahren zur herstellung von 4'-azidocytidinderivaten
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
WO2005018545A3 (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
ATE548353T1 (de) Verfahren zur herstellung von substituierte n- aryl-n'-ä3-(1h-pyrazol-5-yl)phenylü-harnstoffe and intermediate davon.
DE602004023102D1 (de) Verfahren zur herstellung kristalliner formen von orlistat
DE60307749D1 (de) Verwendung von Flavonoid-Derivaten zur Behandlung von atopischem Ekzem
ATE399758T1 (de) Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
DE60222286D1 (de) Verfahren zur erhöhung des testosteronspiegels
DE602004021358D1 (de) Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
ATE497958T1 (de) Verfahren zur herstellung von synthetischen derivaten von dibenzylbutyrolacton-lignanen mit antichagas eigenschaften

Legal Events

Date Code Title Description
8364 No opposition during term of opposition